Goldman Sachs asks: 'Is curing patients a sustainable business model?'
cnbc.com
cnbc.com
One time incentives are always super attractive for employees and staff, although not so much for investors.
Each country has to decide whether to shoulder the responsiblity of citizen health, or leave it to the market.
When we act in concert through markets we tend to say "life is cheap and I don't really care that badly."
People always lament and say that the market gets it wrong but does it? Or is the truth about how we really feel just a little too horrifying uncomfortable?
"I" doesn't make sense in that context. I could change it to "people" but I don't think I'm excluded from the behavioral pattern, so "we" it is.
I value the life of most people I don’t know at a few cents, looking at my past behaviour (buy the simplest of unnecessary things instead of donating to African child vaccination).
The Goldman Sachs analyst was really not that cold blooded
There’s a bit of kabuki in pharma pitches: on one hand you have to talk about how you care about patient suffering, on the other hand you need to cosmetically sugar coat yet emphasize the revenue model, which is what people really care about.
(Oh and the best pitch decks always have gory pictures in them)
The idea of selling of goods predates any government. In their simplest form, how a market operates is determined by the agreement two people, a seller and a buyer for an exchange
When restrictions are applied, how the market operates is still determined by how people interact within those rules or by how they attempt to circumvent them to make their exchange.
This is not a unique case.
However - how would you define a partial cure? Or reward improvements to a cure? A cancer drug that works 60% of the time? 80% of the time? Etc.